DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
作者信息
Pommier Yves
机构信息
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
出版信息
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.
Abstract
摘要
相似文献
1
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.
2
Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
Ann N Y Acad Sci. 2000;922:56-64. doi: 10.1111/j.1749-6632.2000.tb07025.x.
3
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Mol Cancer Ther. 2006 Feb;5(2):287-95. doi: 10.1158/1535-7163.MCT-05-0456.
4
Camptothecins as probes of the microenvironments of topoisomerase I--DNA complexes.
Ann N Y Acad Sci. 2000;922:76-91. doi: 10.1111/j.1749-6632.2000.tb07027.x.
5
Iridoids as DNA topoisomerase I poisons.
J Enzyme Inhib Med Chem. 2005 Aug;20(4):389-92. doi: 10.1080/14756360500141879.
6
Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
Ann N Y Acad Sci. 1996 Dec 13;803:74-92. doi: 10.1111/j.1749-6632.1996.tb26378.x.
7
Topoisomerase I inhibitors: camptothecins and beyond.
Nat Rev Cancer. 2006 Oct;6(10):789-802. doi: 10.1038/nrc1977.
8
Structural insights into the function of type IB topoisomerases.
Curr Opin Struct Biol. 1999 Feb;9(1):29-36. doi: 10.1016/s0959-440x(99)80005-0.
9
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Biochemistry. 1999 Nov 23;38(47):15556-63. doi: 10.1021/bi990947h.
10
Cellular resistance to camptothecins.
Ann N Y Acad Sci. 1996 Dec 13;803:60-73. doi: 10.1111/j.1749-6632.1996.tb26377.x.
引用本文的文献
1
Quinoline derivatives' biological interest for anti-malarial and anti-cancer activities: an overview.
RSC Adv. 2025 Aug 27;15(37):30576-30604. doi: 10.1039/d5ra00534e. eCollection 2025 Aug 22.
2
CUSP06, a Novel CDH6-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Multiple CDH6-Expressing Human Cancer Models.
Pharmaceutics. 2025 Aug 13;17(8):1049. doi: 10.3390/pharmaceutics17081049.
3
Potent β-lactam-based tyrosyl-DNA phosphodiesterase 1 inhibitors identified by a virtual screen.
Sci Rep. 2025 Jul 21;15(1):26510. doi: 10.1038/s41598-025-12503-8.
4
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.
bioRxiv. 2025 Jul 10:2025.07.06.663368. doi: 10.1101/2025.07.06.663368.
5
DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses.
Sci Rep. 2025 Jul 2;15(1):23330. doi: 10.1038/s41598-025-06705-3.
6
A BiO-TiO Heterojunction for Triple-Modality Cancer Theranostics.
Int J Nanomedicine. 2025 Apr 29;20:5593-5610. doi: 10.2147/IJN.S511891. eCollection 2025.
7
Identification of low-toxicity DNA topoisomerase I inhibitors with potential blood-brain barrier penetrability for glioblastoma therapy: structure-based virtual screening reveals promising novel Scaffolds.
Mol Divers. 2025 Apr 16. doi: 10.1007/s11030-025-11185-8.
8
Phosphine Oxide Indenoquinoline Derivatives: Synthesis and Biological Evaluation as Topoisomerase I Inhibitors and Antiproliferative Agents.
Molecules. 2024 Dec 19;29(24):5992. doi: 10.3390/molecules29245992.
9
Mechanisms of tandem duplication in the cancer genome.
DNA Repair (Amst). 2025 Jan;145:103802. doi: 10.1016/j.dnarep.2024.103802. Epub 2024 Dec 25.
10
Modulation of AAV transduction and integration targeting by topoisomerase poisons.
Mol Ther Methods Clin Dev. 2024 Oct 28;32(4):101364. doi: 10.1016/j.omtm.2024.101364. eCollection 2024 Dec 12.
本文引用的文献
1
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
Mol Cancer Ther. 2009 Jul;8(7):1878-84. doi: 10.1158/1535-7163.MCT-09-0016. Epub 2009 Jul 7.
2
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Mol Cancer Ther. 2009 May;8(5):1008-14. doi: 10.1158/1535-7163.MCT-08-0706. Epub 2009 Apr 21.
3
Targeting DNA topoisomerase II in cancer chemotherapy.
Nat Rev Cancer. 2009 May;9(5):338-50. doi: 10.1038/nrc2607. Epub 2009 Apr 20.
4
DNA topoisomerase II and its growing repertoire of biological functions.
Nat Rev Cancer. 2009 May;9(5):327-37. doi: 10.1038/nrc2608. Epub 2009 Apr 20.
5
A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan.
Nucleic Acids Res. 2009 Mar;37(4):e26. doi: 10.1093/nar/gkn1087. Epub 2009 Jan 16.
6
Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay.
Mol Cancer Ther. 2009 Jan;8(1):240-8. doi: 10.1158/1535-7163.MCT-08-0878.
7
An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues.
J Nat Prod. 2009 Jan;72(1):2-7. doi: 10.1021/np800455b.
8
GammaH2AX and cancer.
Nat Rev Cancer. 2008 Dec;8(12):957-67. doi: 10.1038/nrc2523. Epub 2008 Nov 13.
9
DNA cleavage assay for the identification of topoisomerase I inhibitors.
Nat Protoc. 2008;3(11):1736-50. doi: 10.1038/nprot.2008.174.
10
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Mol Cancer Ther. 2008 Oct;7(10):3212-22. doi: 10.1158/1535-7163.MCT-08-0568.
Zotero 插件